Pharma Two B: Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer

Press Release: Pharma Two B : Pharma Two B Announces Publication of Positive Phase 3 Study Results of P2B001, an Investigational Treatment for Early Parkinson's Disease, in Movement Disorders

Pharma Two B: Revolutionary Jab Alleviates Parkinson's Symptoms In New Study

Press Release: Pharma Two B : Pharma Two B to Present Additional Phase 3 Positive Results of P2B001, a once-daily, fixed-dose combination of low-dose pramipexole and low-dose rasagiline, at 2023 International Congress of Parkinson

Pharma Two B: Pharma Two B to Present Additional Positive Results from

Press Release: Pharma Two B : Pharma Two B Presents Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at the MDS International Congress of Parkinson's Disease and Movement Disorders

Pharma Two B: Pharma Two B to Host a Virtual KOL Event on Successful Phase III Study Results of P2B001 in Parkinson's Disease (PD)